{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:32:34Z","timestamp":1771342354490,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1093\/ndt\/gfh966","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T00:41:40Z","timestamp":1121820100000},"page":"2186-2193","source":"Crossref","is-referenced-by-count":109,"title":["Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl"],"prefix":"10.1093","volume":"20","author":[{"given":"Sharon M.","family":"Moe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Rosansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Urena-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moetaz B.","family":"Albizem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter J.","family":"Zani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"key\n\t\t\t\t20171011054533_BIB1","doi-asserted-by":"crossref","unstructured":"Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis1997; 29: 862\u2013865","DOI":"10.1016\/S0272-6386(97)90459-5"},{"key":"key\n\t\t\t\t20171011054533_BIB2","doi-asserted-by":"crossref","unstructured":"Owada A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail2003; 25: 595\u2013602","DOI":"10.1081\/JDI-120022551"},{"key":"key\n\t\t\t\t20171011054533_BIB3","doi-asserted-by":"crossref","unstructured":"Slatapolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int1999; 73: S14\u2013S19","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"key\n\t\t\t\t20171011054533_BIB4","doi-asserted-by":"crossref","unstructured":"Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis2000; 36: 1115\u20131121","DOI":"10.1053\/ajkd.2000.19812"},{"key":"key\n\t\t\t\t20171011054533_BIB5","doi-asserted-by":"crossref","unstructured":"Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci2000; 320: 100\u2013106","DOI":"10.1097\/00000441-200008000-00007"},{"key":"key\n\t\t\t\t20171011054533_BIB6","doi-asserted-by":"crossref","unstructured":"Moe SM, Drueke TB. Management of secondary hyperparathyroidism: The importance and challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol2003; 23: 369\u2013379","DOI":"10.1159\/000073945"},{"key":"key\n\t\t\t\t20171011054533_BIB7","doi-asserted-by":"crossref","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephro2004; 15: 2208\u20132218","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"key\n\t\t\t\t20171011054533_BIB8","doi-asserted-by":"crossref","unstructured":"Ribiero S, Ramos A, Brandao A et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant1998; 13: 2037\u20132040","DOI":"10.1093\/ndt\/13.8.2037"},{"key":"key\n\t\t\t\t20171011054533_BIB9","doi-asserted-by":"crossref","unstructured":"Goodman WG, Goldin J et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med2000; 342: 1478\u20131483","DOI":"10.1056\/NEJM200005183422003"},{"key":"key\n\t\t\t\t20171011054533_BIB10","doi-asserted-by":"crossref","unstructured":"Block GA, Hulbert-Shearson TE, Levin NW, Port FK. Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis1998; 31: 607\u2013617","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"key\n\t\t\t\t20171011054533_BIB11","doi-asserted-by":"crossref","unstructured":"Llach F. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int1999; 56: S31\u2013S37","DOI":"10.1046\/j.1523-1755.1999.07316.x"},{"key":"key\n\t\t\t\t20171011054533_BIB12","doi-asserted-by":"crossref","unstructured":"Block GA, Port FK. Re-evaluation of the risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis2000; 35: 1226\u20131237","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"key\n\t\t\t\t20171011054533_BIB13","doi-asserted-by":"crossref","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca \u00d7 PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol2001; 12: 2131\u20132138","DOI":"10.1681\/ASN.V12102131"},{"key":"key\n\t\t\t\t20171011054533_BIB14","doi-asserted-by":"crossref","unstructured":"Levin NW, Hoenich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphate product in dialysis patients. Curr Opin Nephrol Hypertens2001; 10: 563\u2013568","DOI":"10.1097\/00041552-200109000-00003"},{"key":"key\n\t\t\t\t20171011054533_BIB15","doi-asserted-by":"crossref","unstructured":"Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int2001; 59: 1187\u20131201","DOI":"10.1046\/j.1523-1755.2001.0590031187.x"},{"key":"key\n\t\t\t\t20171011054533_BIB16","doi-asserted-by":"crossref","unstructured":"Eknoyan G, Levin A, Levin NW. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 42: s1\u2013s201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"key\n\t\t\t\t20171011054533_BIB17","doi-asserted-by":"crossref","unstructured":"Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perti Dial Int2000; 20: 315\u2013321","DOI":"10.1177\/089686080002000308"},{"key":"key\n\t\t\t\t20171011054533_BIB18","doi-asserted-by":"crossref","unstructured":"Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium\u2009\u00d7phosphorus in secondary hyperparathyroidism. Kidney Int2003; 63: 248\u2013254","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"key\n\t\t\t\t20171011054533_BIB19","doi-asserted-by":"crossref","unstructured":"Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol2003; 14: 575\u2013583","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"key\n\t\t\t\t20171011054533_BIB20","doi-asserted-by":"crossref","unstructured":"Block GA, Martin KJ, de Francisco AML et al. The calcimimetic cinacalcet hydrochloride (AMG 073) for the treatment of secondary hyperparathyroidism in hemodialysis patients. N Engl J Med2004; 350: 1516\u20131525","DOI":"10.1056\/NEJMoa031633"},{"key":"key\n\t\t\t\t20171011054533_BIB21","doi-asserted-by":"crossref","unstructured":"Moe SM, Coburn JW, Quarles LD et al. Achievement of proposed NKF-K\/DOQI Bone Metabolism and Disease targets: Treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (HPT). Kid Int2005; 67:760\u2013771","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"key\n\t\t\t\t20171011054533_BIB22","doi-asserted-by":"crossref","unstructured":"Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrod DJ. Intravenous calcitriol in the treatment of refractory posterities fibrosis of chronic renal failure. N Engl J Med1989; 321: 274\u2013279","DOI":"10.1056\/NEJM198908033210502"},{"key":"key\n\t\t\t\t20171011054533_BIB23","doi-asserted-by":"crossref","unstructured":"Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis1995; 26: 836\u2013844","DOI":"10.1016\/0272-6386(95)90453-0"},{"key":"key\n\t\t\t\t20171011054533_BIB24","doi-asserted-by":"crossref","unstructured":"Heaf J. Causes and consequences of adynamic bone disease. Nephron. 2001; 88: 97\u2013106","DOI":"10.1159\/000045968"},{"key":"key\n\t\t\t\t20171011054533_BIB25","unstructured":"Malluche HH, Monier-Faugere MC, Wang G et al. Cinacalcet HCL reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant2004; 218b, abstract MO16"},{"key":"key\n\t\t\t\t20171011054533_BIB26","doi-asserted-by":"crossref","unstructured":"Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol2002; 13: 1017\u20131024","DOI":"10.1681\/ASN.V1341017"},{"key":"key\n\t\t\t\t20171011054533_BIB27","doi-asserted-by":"crossref","unstructured":"Ishizuya T, Yokose S, Hori M et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Investigation1997; 99: 2961\u20132970","DOI":"10.1172\/JCI119491"},{"key":"key\n\t\t\t\t20171011054533_BIB28","unstructured":"Wada M, Furuya Y, Kobayashi N et al. The calcimimetic compound AMG 073 (cinacalcet HCl) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol2003; 14: 48A, abstract SU-FC218"},{"key":"key\n\t\t\t\t20171011054533_BIB29","doi-asserted-by":"crossref","unstructured":"Wada M, Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant2003; 18: III13\u2013III17","DOI":"10.1093\/ndt\/gfg1004"},{"key":"key\n\t\t\t\t20171011054533_BIB30","doi-asserted-by":"crossref","unstructured":"Martin KJ, Gonzalez E, Lindberg JS et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis2001; 38: S57\u2013S63","DOI":"10.1053\/ajkd.2001.28112"},{"key":"key\n\t\t\t\t20171011054533_BIB31","doi-asserted-by":"crossref","unstructured":"Maung HM, Elangovan L, Frazao JM et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1\u03b1-hydroxyvitamine D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis2001; 37: 532\u2013543","DOI":"10.1053\/ajkd.2001.22077"},{"key":"key\n\t\t\t\t20171011054533_BIB32","doi-asserted-by":"crossref","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batile D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int2003; 63: 1483\u20131490","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"key\n\t\t\t\t20171011054533_BIB33","doi-asserted-by":"crossref","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med2003; 349: 446\u2013456","DOI":"10.1056\/NEJMoa022536"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/20\/10\/2186\/5450515\/gfh966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:43:30Z","timestamp":1626205410000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/20\/10\/2186\/1934483\/Longterm-treatment-of-secondary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2005,7,19]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfh966","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,7,19]]}}}